Published in Antimicrob Agents Chemother on October 27, 2014
A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med (1999) 82.86
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol (2013) 5.64
Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir. Hepatology (2013) 3.68
Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther (2008) 2.56
Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther (2005) 1.81
Hepatitis C and renal disease: an update. Am J Kidney Dis (2003) 1.65
Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol (2010) 1.63
Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol (2009) 1.51
Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. Antimicrob Agents Chemother (2010) 1.49
Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol (2001) 1.39
Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial. Hepatology (2013) 1.28
The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol (2008) 1.26
Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr Drug Metab (2003) 1.14
Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial. Hepatology (2013) 1.14
The high comorbidity burden of the hepatitis C virus infected population in the United States. BMC Infect Dis (2012) 1.10
Effects of drug transporters on volume of distribution. AAPS J (2009) 1.01
Downregulation of intestinal cytochrome p450 in chronic renal failure. J Am Soc Nephrol (2002) 1.00
In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporter-enzyme interplay. Drug Metab Dispos (2006) 1.00
Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study. Liver Int (2014) 0.93
Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection. Liver Int (2013) 0.93
Mechanisms underlying benign and reversible unconjugated hyperbilirubinemia observed with faldaprevir administration in hepatitis C virus patients. J Pharmacol Exp Ther (2014) 0.92
Bridging in vitro and in vivo metabolism and transport of faldaprevir in human using a novel cocultured human hepatocyte system, HepatoPac. Drug Metab Dispos (2013) 0.83
Mass balance and metabolite profiling of steady-state faldaprevir, a hepatitis C virus NS3/4 protease inhibitor, in healthy male subjects. Antimicrob Agents Chemother (2014) 0.79
HCV-targeted antivirals: current status and future challenges. Curr Pharm Des (2014) 0.78
Generating an in vitro-in vivo correlation for metabolism and liver enrichment of a hepatitis C virus drug, faldaprevir, using a rat hepatocyte model (HepatoPac). Drug Metab Dispos (2013) 0.78
Pharmacokinetics of Teneligliptin in Subjects With Renal Impairment. Clin Pharmacol Drug Dev (2013) 0.90
Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment. Clin Pharmacol Drug Dev (2014) 0.81
Pharmacokinetics and safety of olodaterol administered with the Respimat Soft Mist inhaler in subjects with impaired hepatic or renal function. Int J Chron Obstruct Pulmon Dis (2016) 0.77
Effect of steady-state faldaprevir on the pharmacokinetics of steady-state methadone and buprenorphine-naloxone in subjects receiving stable addiction management therapy. Antimicrob Agents Chemother (2014) 0.75
Effect of the hepatitis C virus protease inhibitor faldaprevir on the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers. Antimicrob Agents Chemother (2014) 0.75
Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals With Renal Impairment. Clin Pharmacol Drug Dev (2016) 0.75
Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals with Mild or Moderate Hepatic Impairment. Eur J Drug Metab Pharmacokinet (2019) 0.75
Pharmacokinetics and safety of letermovir, a novel anti-human cytomegalovirus drug, in patients with renal impairment. Br J Clin Pharmacol (2017) 0.75